CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 83 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q2 2018. The put-call ratio across all filers is 1.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $18,000 | -89.8% | 29,954 | -69.4% | 0.00% | – |
| Q3 2021 | $177,000 | -14.5% | 97,791 | -13.8% | 0.00% | – |
| Q2 2021 | $207,000 | +314.0% | 113,421 | +341.0% | 0.00% | – |
| Q1 2021 | $50,000 | -41.9% | 25,718 | -62.7% | 0.00% | – |
| Q4 2020 | $86,000 | -82.3% | 68,947 | -74.6% | 0.00% | -100.0% |
| Q3 2020 | $487,000 | -38.7% | 271,023 | +186.4% | 0.00% | 0.0% |
| Q2 2020 | $794,000 | +2546.7% | 94,645 | +1509.1% | 0.00% | – |
| Q1 2020 | $30,000 | -72.7% | 5,882 | -71.0% | 0.00% | – |
| Q4 2019 | $110,000 | 0.0% | 20,306 | +7.1% | 0.00% | – |
| Q4 2018 | $110,000 | -37.5% | 18,966 | -19.0% | 0.00% | -100.0% |
| Q3 2018 | $176,000 | +1855.6% | 23,422 | +1479.4% | 0.00% | – |
| Q1 2018 | $9,000 | -92.5% | 1,483 | -91.3% | 0.00% | -100.0% |
| Q4 2017 | $120,000 | -18.4% | 17,011 | -27.5% | 0.01% | -16.7% |
| Q2 2017 | $147,000 | +113.0% | 23,458 | +185.9% | 0.01% | +50.0% |
| Q4 2016 | $69,000 | +146.4% | 8,204 | +96.2% | 0.00% | +100.0% |
| Q3 2016 | $28,000 | – | 4,181 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $5,147,000 | 2.57% |
| ETF MANAGERS GROUP, LLC | 14,101,511 | $14,243,000 | 0.27% |
| Ikarian Capital, LLC | 948,526 | $968,000 | 0.07% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 289,627 | $295,000 | 0.04% |
| Platform Technology Partners | 60,000 | $61,000 | 0.03% |
| PINNACLE ASSOCIATES LTD | 966,014 | $985,000 | 0.02% |
| XTX Topco Ltd | 41,599 | $42,000 | 0.01% |
| Virtu Financial LLC | 160,380 | $164,000 | 0.01% |
| Tekla Capital Management LLC | 413,481 | $422,000 | 0.01% |
| Aries Wealth Management | 23,400 | $24,000 | 0.01% |